[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:homologous-recombination-repair-gene":3},{"name":4,"total":5,"recruiting":5,"trials":6},"Homologous Recombination Repair Gene",2,[7,15],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT05188508","Pembrolizumab, Olaparib, and Temozolomide for People With Glioma",[11],"Phase 2","RECRUITING","2026-08-26T02:17:43.321968Z","2026-05-05T02:43:27.089223Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":19,"content_modified":20},"NCT05700721","Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)",[11],"2026-08-26T02:19:26.493949Z","2026-05-05T02:43:26.981975Z"]